H
14.84
-0.28 (-1.85%)
| 前收盘价格 | 15.12 |
| 收盘价格 | 14.86 |
| 成交量 | 36,149 |
| 平均成交量 (3个月) | 99,990 |
| 市值 | 2,588,808,448 |
| 市盈率 (P/E TTM) | 74.20 |
| 预期市盈率 (P/E Forward) | 47.85 |
| 价格/销量 (P/S) | 4.24 |
| 股市价格/股市净资产 (P/B) | 3.43 |
| 52周波幅 | |
| 利润日期 | 29 Jul 2025 - 4 Aug 2025 |
| 营业毛利率 | 5.99% |
| 营业利益率 (TTM) | -4.99% |
| 稀释每股收益 (EPS TTM) | 0.200 |
| 季度收入增长率 (YOY) | 6.40% |
| 季度盈利增长率 (YOY) | -84.70% |
| 总债务/股东权益 (D/E MRQ) | 11.64% |
| 流动比率 (MRQ) | 2.83 |
| 营业现金流 (OCF TTM) | -46.98 M |
| 杠杆自由现金流 (LFCF TTM) | -50.75 M |
| 资产报酬率 (ROA TTM) | -2.14% |
| 股东权益报酬率 (ROE TTM) | 5.04% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
| 股票 | HUTCHMED (China) Limited | 混合的 | 看跌 |
AIStockmoo 评分
-0.8
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.75 |
|
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Mid Value |
| 内部持股比例 | 0.12% |
| 机构持股比例 | 4.03% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Aia Group Ltd | 31 Dec 2024 | 315,439 |
| Catalyst Funds Management Pty Ltd | 31 Dec 2024 | 142,231 |
| Hennion & Walsh Asset Management, Inc. | 31 Mar 2025 | 48,769 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合